Developer docs
API playgroundTry for free, no card

Search company profiles

Vibalogics

Full company profile

uuid002br6v

Namestring
Vibalogics
Company typeenum
Private
Founded yearint
2001
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersCuxhaven, Germany
HQ citystring
Cuxhaven
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

No data
Social media profiles1 record
No data
Differentiator
Functional benefit
Problem solved
No data
Market position
Customer concentration

Classification, Details

No data
API detail

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Vibalogics

Vibalogics firmographics

Firmographics
Name
Vibalogics
Website
https://vibalogics.com/
Company type
Private
Founded year
2001
Headcount range
251–500 employees
Ownership category
akta.pro rank

Where Vibalogics is headquartered

Location

Headquarters

HQ city
Cuxhaven
HQ country
Germany
HQ region
Europe

Markets served

Vibalogics technology and API

Technology

API detail

API docs
API detail

Core technology

AI maturity

App detail

Vibalogics competitors and assessment

Company assessment

Market position

Customer concentration

Vibalogics social profiles

Digital presence

Vibalogics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Vibalogics leadership team

Management profile

Number of profiles

Vibalogics funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Vibalogics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vibalogics

When was Vibalogics founded?

Vibalogics was founded in 2001. It employs 251 to 500 people.

Where is Vibalogics based?

Vibalogics is headquartered in Cuxhaven, Germany, in the Europe region.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioProcess InternationalRecipharm bolsters biologics biz with Vibalogics buyRecipharm has acquired Vibalogics, a virotherapy CDMO, to expand its advanced therapy medicinal products (ATMPs) offering into virotherapies. The deal allows Recipharm to leverage Vibalogics' expertise in viral vaccines and gene therapies, while also strengthening its presence with US customers. This acquisition is part of a broader strategy that includes recent purchases of Arranta Bio and GenIbet.Drug Development and DeliveryRecipharm Announces Acquisition of Vibalogics & Arranta BioRecipharm announced the simultaneous acquisition of Vibalogics and Arranta Bio to expand its contract development and manufacturing organization (CDMO) capabilities in advanced therapy medicinal products. This strategic move integrates specialized virotherapy and microbiome/mRNA manufacturing expertise, strengthening Recipharm's presence in the US market. The transactions are expected to complete around the end of March 2022.GlobeNewswireViral Vector Manufacturing Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)The viral vector manufacturing market was estimated at USD 601.36 million in 2020 and is projected to reach USD 2,579.85 million by 2026, a CAGR of 27.36%. Growth is driven by rising cancer cases, clinical trials, and investments like Vibalogics' $150 million facility. North America currently dominates the market.Manufacturing ChemistNavigating the maelstrom of M&A activity: what do CDMOs do next?A panel discussion on contract development and manufacturing organisation (CDMO) consolidation featured executives from Cognizant, Samsung Biologics and Vibalogics discussing M&A trends. Participants cited drivers including expanded capabilities, faster market entry and geographical expansion, with DCAT noting 15 major deals in 2021. They said consolidation is expected to continue through 2022.BioProcess InternationalVector market moving in right directionA shortage of viral vector manufacturing capacity for gene therapies has emerged as a key driver of M&A activity in the contract development and manufacturing (CDMO) space. Major acquisitions by Catalent and Thermo Fisher, as well as Ampersand Capital Partners' purchase of German vector specialist Vibalogics GmbH, underscore the strategic value of viral vector capacity amid tight supply. With 24 gene therapies currently in Phase III development, industry experts warn that manufacturing capacity may struggle to meet demand as these therapies approach market approval.PR NewswireAmpersand Capital Partners to Acquire Vibalogics GmbHAmpersand Capital Partners, a private equity firm specializing in healthcare growth equity investments, has agreed to acquire Vibalogics GmbH, a German contract development and manufacturing organization focused on complex live biological products. The growth investment will enable Vibalogics to expand its capabilities in developing and manufacturing viral products including oncolytic viral therapies, gene therapies, and vaccines, while strengthening its presence in US and European markets. The partnership aims to accelerate Vibalogics' growth trajectory and support the development of innovative therapeutic approaches for cancer and genetic disorders.